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Korean-Specific Parameter Models for Calculating the Risk of 
Down Syndrome in the Second Trimester of Pregnancy
The purpose of the current study was to propose a Korean-specific parameter set for 
calculating the risk of Down syndrome in the second trimester of pregnancy and to 
determine the screening performances of triple and quadruple tests in Korean women. 
Using the data on triple or quadruple screening from three hospitals in Korea during 7 yr, 
we re-converted the concentrations of four serum markers to multiple of median values 
according to gestational age and maternal weight. After re-calculating the risk of Down 
syndrome in each pregnancy by multiplying maternal age-specific risk by the likelihood 
ratio values for the serum markers, screening performances and optimal cut-off values of 
triple and quadruple tests were analyzed. Among 16,077 pregnancies, 23 cases had Down 
syndrome (1.4/1,000 deliveries). Compared to the previous program, the tests with new 
parameters had improved screening performance. The triple and quadruple tests had 
detection rates of 65.2% and 72.7%, respectively, at a false-positive rate of 5%. The 
optimal cut-off value for the quadruple and triple tests was 1:250. We have presented a 
Korean-specific parameter set for Down syndrome screening. The proposed screening test 
using this parameter set may improve the performance of Down syndrome screening for 
Korean women.
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INTRODUCTION
Down syndrome is the most common chromosomal anomaly, 
with an incidence at birth of 1 per 800-1,000 (1, 2). Amniocen-
tesis or chorionic villous sampling for prenatal chromosomal 
analysis is difficult to be performed in all patients because of the 
risk of fetal loss and the cost (3). Accordingly, prenatal screening 
to identify pregnancies at increased risks for Down syndrome is 
very important. 
  Since Cuckle et al. (4) reported that a low level of serum α- fe-
toprotein (AFP) is a high-risk marker for Down syndrome in 1984, 
several maternal serum markers have been developed. Mea-
suring maternal serum levels of AFP, total human chorionic go-
nadotrophin (hCG), and unconjugated estriol (uE3) is known 
as triple screening (5, 6). The quadruple test, which adds inhib-
in A, was introduced in the early 2000s (7, 8). To calculate the 
risk of Down syndrome using serum markers, commercially 
available software programs are used in practice. Because vari-
ances are observed between software programs, it is effective 
that each country has a software program to apply variances and 
covariances of serum markers for its own population to achieve 
accurate screening.
  In Korea, the triple and quadruple tests have been used wide-
ly among pregnant women since December 2004 and October 
2009 under the support of National Health Insurance, respec-
tively. However, the accuracy of Down syndrome screening tests 
is questionable in Korea, because the software programs in use 
were mainly based on dataset compiled from Western women. 
In addition, little information is available on the performance 
of these screening tests for Korean women. Few reports have 
analyzed the performance of triple screening in Korea, but the 
sample sizes were small (9, 10). 
  Recently, ethnic differences in serum marker levels have been 
reported (11-13), and the maternal age-related risk for Down syn-
drome was also reported to be different among races (14). There-
fore, it is requested to establish screening tests specific for each 
race or region (15). Accordingly, in this study, we determined the 
covariances of serum markers for triple and quadruple screen-
ing tests in a Korean population, and re-calculated the risk of 
Down syndrome using newly determined values. Then, we com-
pared the performances with those by software currently in use. 
This study introduces a dataset for Down syndrome serum screen-
ing and cut-off values specific for pregnant Korean women.Kwon JY, et al.  •  Korean-specific Calculating Models for Down Syndrome 
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MATERIALS AND METHODS
Study participants
We analyzed the medical records of all pregnant Korean women 
who underwent triple or quadruple screening test between 14 
and 21 weeks gestation at Seoul St. Mary’s Hospital and Yeouido 
St. Mary’s Hospital (2002-2009), and Cheongwha Women’s Med-
ical Center (2005-2009). A total of 17,890 pregnant women had 
second trimester screening tests; 1,813 pregnant women who 
had no records on fetal outcomes were excluded and 16,077 preg-
nant women were analyzed. Based on the records of screening 
tests, we determined the serum levels of AFP, hCG, uE3, and in-
hibin A, and the expected risk of Down syndrome. For those 
pregnant women who underwent amniocenteses, we checked 
the karyotype results, and for the pregnant women who did not 
undergo amniocenteses, we investigated the presence of fetal 
Down syndrome using neonatal charts on the date of birth and 
1 month after birth. 
Screening performances of triple and quadruple tests 
based on the HIT program
Gestational age (GA) was estimated by the menstrual history if 
regular or by ultrasonographic scan. Maternal age referred to age 
at the time of expected delivery date. Maternal serum levels of 
AFP, hCG, uE3, and inhibin A were determined using the Unicel
TM 
Dxl 800 Access Immunoassay System with reagents (Beckman 
Coulter
®, Inc., Fullerton, CA, USA). The screening performances 
of the triple or quadruple tests based on the HIT program (Ham-
choon Inc., Seoul, Korea) with a cut-off value of 1:270 were cal-
culated.
Down syndrome risk assessment using newly established 
parameters of serum markers 
To correct the variable changes in serum marker concentrations 
according to gestational age, the concentrations were convert-
ed to multiple of the median (MoM) values for the relevant ges-
tational ages. To provide reliable medians, regression analysis of 
each serum marker on gestational age among unaffected preg-
nancies was performed using the median concentration of each 
serum marker and median gestation (in days) for pregnancies 
at each completed week of pregnancy, weighted for the number 
of women at each week. The MoMs were calculated separately 
in each hospital according to the median values obtained from 
following regression equations: AFP (ng/mL) = 10
(0.7569 + 0.0078 * GA); 
hCG (IU/mL) = 10
(6.5772 - 0.0733 * GA + 0.0003 * GA * GA); uE3 (ng/mL) = -4.4196 
+ 0.0499 * GA; Inhibin A (pg/mL) = 10
(0.7569 + 0.0078 * GA). 
  And then, all of the MoMs for the four serum markers were 
corrected for maternal weight using the weighted median re-
gression method. The median MoMs were calculated separate-
ly in the 14 maternal weight groups (at 5-kg intervals). The val-
ues were then weighted by frequency, and subjected to regres-
sion estimation together with the median maternal weight of 
the corresponding weight group. Among simple linear, quadrat-
ic, log-linear, and log-quadratic regression models, the most suit-
able model was based on the multiple determination coeffecients 
(the R square). The weight-adjusted MoMs were calculated ac-
cording to the following formula: AFP corr = AFP MoM observed/AFP 
MoM expected, where MoM expected was calculated according to the 
selected regressed equation: AFP (MoMs) = 2.2856 - 0.0328 * kg 
+ 0.0002 * kg * kg; hCG (MoMs)  =  10
(0.2636 - 0.0047 * kg); uE3 (MoMs) =  
10
(0.1848 - 0.0043 * kg + 0.00002 * kg * kg);. inhibin A (MoMs) = 10
(0.3085-0.0078 * kg 
+0.00004 * kg * kg).
  All weight-corrected MoM values were converted to log-equiv-
alents to obtain the distribution parameters. Goodness-of-fit to 
log-Gaussian distribution for the marker values was judged by 
inspection of the log-probability plot for unaffected pregnan-
cies and the Kolmogorov-Smirnov test for affected pregnancies. 
Upper and lower truncation limits were set within which the 
available data adequately fitted the Gaussian model judged by 
inspection of the log-probability plot. Values outside those lim-
its were given MoM values at the appropriate limit. The trunca-
tion limits for markers were 0.5-2.0 MoM for AFP, 0.3-2.7 MoM 
for uE3, 0.5-1.7 MoM for hCG, and 0.5-2.1 MoM for inhibin A. 
  The mean and standard deviations for each marker in unaf-
fected and affected pregnancies were calculated by using the 
log10 of the median as the mean. The risk of Down syndrome 
was assessed by a commonly used risk algorithm. The likelihood 
ratio (LR) obtained with each marker was the height of the Gauss-
ian distribution for the Down syndrome pregnancies divided by 
the height of the Gaussian distribution for the unaffected preg-
nancies at the particular value of the variables concerned. Age-
specific risk was derived from the previous report of maternal 
age-specific rates of Down syndrome in Korean pregnant wom-
en (13). 
  The case-specific risks of Down syndrome in triple and qua-
druple tests were estimated using the following equations: risk 
with triple screening = risk age * LR (AFP) * LR (HCG) * LR (uE3); 
risk with quadruple screening = risk age × LR (AFP) * LR (HCG) 
* LR (uE3) * LR (inhibin A).
Statistical analysis
We compared the incidence of Down syndrome between preg-
nancies in which the maternal age was < 35 yr and pregnancies 
in which the maternal age was ≥ 35 yr by Student’s t-test. The 
median concentrations and MoMs of the serum markers were 
compared with published values for Caucasian women for the 
relevant gestational age by calculating the ratio. The MoM val-
ues of serum markers between unaffected and Down syndrome 
pregnancies were compared using Student’s t-test.
  Detection and false-positive rates for Down syndrome were 
re-calculated for all pregnancies. In particular, to determine the 
optimal cut-off value, we constructed the area under the receiver Kwon JY, et al.  •  Korean-specific Calculating Models for Down Syndrome 
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operating characteristic (AUROC) curve. A P value < 0.05 was 
considered statistically significant. All statistical analyses were 
carried out using SPSS (version 12.0; SPSS Inc., Chicago, IL, USA).
Ethics statement
The study was approved by the institutional review board of the 
College of Medicine of the Catholic University of Korea (KC10-
RES10193, SC11RIM10074). The board waived informed con-
sent from the subject patients. It was conducted in accordance 
with the Declaration of Helsinki.
RESULTS
Demographic characteristics 
Among the 16,077 pregnancies, Down syndrome occurred in 23 
cases (1.4/1,000 newborns). The demographic characteristics of 
the pregnancies included in this study are summarized in Table 
1. The mean maternal age was 31.1 ± 3.5 yr, and the mean ma-
ternal weight was 57.2 ± 8.5 kg. Among the gravidas > 35 yr of 
age, the prevalence of Down syndrome was 5.0 per 1,000 new-
borns, which was significantly higher than the 0.7 per 1,000 new-
borns among the gravidas < 35 yr of age (P = 0.002). 
  Triple and quadruple screening tests were performed on 8,805 
and 7,992 pregnancies, respectively. Among the 23 fetuses with 
Down syndrome, 17 had positive triple or quadruple screening 
tests; 4 and 2 fetuses had negative triple and quadruple screen-
ing tests using the HIT program, respectively. 
The serum concentrations and MoMs of four serum markers 
for Down syndrome and unaffected pregnancies
When the median values of the serum markers at each gestation-
al age were compared with the published values for Caucasian 
women (16), the median values of all the serum markers were 
higher in Korean women than Caucasian women. The range of 
ratios was highest for inhibin A (range, 1.5-1.9), followed by uE3, 
AFP, and hCG (Table 2).
Table 1. Demographic characteristics of all pregnancies and pregnancies complicat-
ed by Down syndrome 
Characteristics
Total pregnancies 
(N = 16,077)
Down syndrome 
pregnancies 
(N = 23)
Maternal age at expected date 
   of delivery (yr)
    <35
    ≥ 35
 
13,499
  2,578
 
10
13
Second trimester screening test*
   Triple test (Women with 
      positive screening) 
   Quadruple test (Women with 
      positive screening)
 
8,085 (595)
7,992 (632)
 
12 (8)
11 (9)
Pregnancies with type 1 diabetics           7   0
Gestational age of fetus at screening test
   14-17 week 
   19-21 week
116.7 ± 7.4 days
14,395
  1,682
115.4 ± 8.2 days
20
  3
Maternal weight  57.2 ± 8.5 kg 59.0 ± 10.4 kg
All data are expressed Number of pregnancies or mean ± SD. *Screening analysis 
using HIT program (Hamchoon Inc., Seoul, Korea) at a cutoff value of 1:270.
Table 2. Comparison of median maternal serum concentrations of AFP, hCG, uE3 and inhibin A between Korean and Caucasian women with unaffected pregnancies
GA (wk)
AFP (ng /mL) hCG (IU/mL) uE3 (ng/mL) Inhibin A (pg/mL)
Korean 
Cauca-
sian*
Ratio
† Korean 
Cauca-
sian*
Ratio
† Korean 
Cauca-
sian*
Ratio
† Korean 
Cauca-
sian*
Ratio
†
15 39.5 33.3 1.2 46.8 42.4 1.1 0.98 0.73 1.4 207 112 1.9
16 44.7 37.6 1.2 36.3 34.1 1.1 1.33 0.92 1.4 184 108 1.7
17 50.7 42.5 1.2 29.8 28.3 1.1 1.68 1.15 1.5 171 104 1.7
18 57.4 48.0 1.2 26.0 24.1 1.1 2.03 1.43 1.4 167 105 1.6
19 65.1 54.3 1.2 24.1 21.2 1.1 2.38 1.79 1.3 170 118 1.5
20 73.8 61.3 1.2 23.6 19.1 1.2 2.73 2.24 1.2 181 124 1.5
All data are expressed as median values. *Data for Caucasian women were reported by MacRae et al. (15); 
†Ratio of the serum markers’ medians calculated in this study to 
those in a published study with Caucasian women for the relevant gestational age. GA, gestational age; wk, week; AFP, α-fetoprotein; hCG, human chorionic gonadotrophin; 
uE3, unconjugated estriol.
Table 3. Statistical variables of log transformed and untransformed Gaussian distributions of each serum marker, expressed in multiple of the median (MoM) values in Down 
syndrome and unaffected pregnancies
Variables
Unaffected pregnancies Down syndrome pregnancies
AFP hCG uE3 Inhibin A AFP hCG uE3 Inhibin A
Mean* 1.05 1.09 1.01 1.08 0.82 2.13 0.73 2.65
Median 1.00 1.00 1.00 1.00 0.82 (0.74)
‡ 1.80 (2.05)
‡ 0.74 (0.70)
‡ 2.54 (2.54)
‡
Log10 means
†  0.00 0.00 0.00 0.00 -0.09 0.26 -0.13 0.41
Log10 S.D. 0.15 0.22 0.16 0.20 0.16 0.20 0.25 0.12
*Comparison between unaffected pregnancies and Down syndrome pregnancies; P = 0.012, 0.001, 0.001, and < 0.001, by Student t test for AFP, hCG, uE3, and inhibin A re-
spectively; 
†The log10 means were estimated from the medians; 
‡Values in parentheses were reported by Wald et al. (16). AFP, α-fetoprotein; hCG, human chorionic gonadotro-
phin; uE3, unconjugated Estriol.Kwon JY, et al.  •  Korean-specific Calculating Models for Down Syndrome 
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  The serum marker levels were converted to MoMs according 
to gestational age and maternal weight and then the MoM level 
of each serum marker was compared between gravidas with preg-
nancies complicated by Down syndrome and gravidas with un-
affected pregnancies. The mean MoM levels of AFP and uE3 in 
pregnancies complicated by Down syndrome were significantly 
lower than in unaffected pregnancies (P = 0.012 and P = 0.001, 
respectively). In addition, the mean MoM levels of hCG and in-
hibin A in pregnancies complicated by Down syndrome were 
significantly higher than in unaffected pregnancies (P = 0.001 
and P < 0.001, respectively; Table 3). The medians and standard 
deviations of the log-Gaussian distribution for each serum mark-
er are summarized in Table 3. For Korean and Caucasian wom-
en with pregnancies complicated by Down syndrome (17), the 
MoMs of serum markers were 0.82 and 0.74 for AFP, 1.80 and 
2.05 for hCG, 0.74 and 0.70 for uE3, and 2.543 and 2.54 for inhib-
in A, respectively.
Screening performance for second trimester screening tests
Using the statistical distributions for each marker, we calculated 
screening performances for triple and quadruple screenings. 
Fig. 1 shows the ‘ROC curves’ that gives the detection and false-
positive rates for the triple and quadruple tests. The AUROC curve 
was highly significant (P < 0.001) for quadruple (AUROC, 0.966; 
95% confidence interval [CI], 0.940-0.991) and triple tests (AU-
ROC, 0.955; 95% CI, 0.927-0.983). Table 4 shows the observed 
screening performances of triple and quadruple tests according 
to various risk cut-off values. The quadruple test achieved a Down 
syndrome detection rate of 81.8%, and the odds of being affect-
ed given a positive result (OAPR) of 1:59 at a risk cut-off value of 
1:250. The triple test achieved a Down syndrome detection rate 
of 69.5% at a risk cut-off value of 1:300, and the OAPR was 1:73.
  When the screening performance using our dataset was com-
pared with the screening performance using the HIT program, 
triple screening showed a slight decrease in the detection rate 
from 66.7% to 65.2%, but a larger decrease in the false-positive 
rate from 7.3% to 6.1%. Quadruple screening also lowered the 
false-positive rate from 7.8% to 6.6% while maintaining the de-
Table 4. Screening performance for Down syndrome with second trimester screening tests according to various risk cut-off values
Screening
Risk cutoff
1 in 150 1 in 200 1 in 250 1 in 270 1 in 300
DR FPR OAPR DR FPR OAPR DR FPR OAPR DR FPR OAPR DR FPR OAPR
Triple 52.2 3.2 1: 40 60.8 4.7 1: 55 65.2 6.1 1: 66 65.2 6.7 1: 69 69.6 7.3 1: 73
Quadruple 72.7 4.7 1: 47 72.7 5.8 1: 57 81.8 6.6 1: 59 81.8 6.8 1: 62 81.8 7.2 1: 64
DR, detection rate (%); FPR, false-positive rate; OAPR, odds of being affected given a positive result.
Table 5. Screening performances of triple and quadruple tests using dataset of this 
study compared with the HIT program
Screening
HIT program  
(Cut off value 1:270)
Program of this study  
(Cut off value 1:250)
Triple screening 
   Detection rate
   False positive rate 
 
66.7%
  7.3%
 
65.2%
  6.1%
Quadruple screening 
   Detection rate
   False positive rate 
 
81.8%
  7.8%
 
81.8%
  6.6%
Fig. 1. Screening perfomances of triple and quadruple screening for Down syndrome risk. (A) ROC curve of quadruple screening (AUROC, 0.966; 95% confidence interval [CI], 
0.940-0.991) and triple screening (AUROC, 0.955; 95% CI, 0.927-0.983) for Down syndrome risk. (B) Down syndrome detection and false-positive rates for quaduple and tri-
ple test.
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tection rate at 81.8% (Table 5). 
 
DISCUSSION
This study established a parameter set of serum markers for tri-
ple and quadruple screening tests in pregnant Korean women. 
This can improve the screening performance of pregnancies 
complicated by Down syndrome compared with the previous 
programs based on a parameter set for Western women. In the 
current study, the detection rates of triple and quadruple screen-
ing were 65.2% and 72.7%, respectively, at a false-positive rate 
of 5%. Compared with the current program, the screening per-
formance using our dataset was much improved. 
  In Korea, the second trimester screening tests have used a cut-
off value of 1:270 since the screening test was implemented. When 
the serum screening markers were under development, a cut-
off value of 1:270 was used to maintain consistency with the ex-
isting cut-off value for previous screening using maternal age 
only, but nowadays when various screening programs are avail-
able, it is not appropriate to apply a cut-off value of 1:270 uni-
formly without considering the screening performance of each 
program. The risk cut-off of a screening test should be set spe-
cifically to each country in consideration of the performance of 
the screening test, the cost and safety of invasive diagnostic pro-
cedures, the prevalence of Down syndrome, and the age distri-
bution of pregnant women in the country. The optimal cut-off 
value for the quadruple screening test using our parameter set 
is considered to be 1:250 (detection rate of 81.8% at a false-posi-
tive rate of 6.6%). In our analysis, a lower cut-off value of 1:350 
led to 79 additional amniocenteses and resulted in the detection 
of 1 additional case of fetal Down syndrome. To improve the de-
tection rate, adopting the first trimester combined screening 
may be efficient rather than lowering the cut-off value in the 
second trimester screeing test. Recent studies have suggested 
that a combination of first trimester screening and second tri-
mester quadruple screening achieved a detection rate of 94%-
96% at a false-positive rate of 5% (17, 18). 
  In the current study, the concentrations of AFP, hCG, uE3, and 
inhibin A were higher on average than the concentrations estab-
lished for the Caucasian population. Ethnic differences have 
been noted in comparisons of black, Caucasian, and Asian pop-
ulations in Europe and the USA (11, 18, 20). It is known that Asian 
women have the highest levels of AFP, hCG, and uE3 (11, 13), 
and our study was in line with the previous studies. In addition, 
we emphasize that the serum level of inhibin A is also the high-
est in Asian women (9). With respect to inhibin A, even though 
some studies have reported that black women have higher lev-
els of inhibin A than Caucasian women (20), a comparison be-
tween Asian and Caucasian women has not been attempted 
thus far. Although the ethnic effect on screening for Down syn-
drome appears to be relatively minor because of the counter-
balancing effect of multiple serum markers (12), correction for 
ethnicity can have a significant impact on individual risk, which 
could alter clinical decision-making (20). 
  The median MoM of hCG in Korean women with a Down syn-
drome pregnancy was 1.80, which was lower compared to 2.01-
2.12 in Caucasian women (21). In Chinese women, the median 
MoM of hCG in Down syndrome pregnancies was 1.4 (13). Al-
though these studies were limited by small sample sizes, the me-
dian MoM of each serum marker in Down syndrome pregnancies 
may reflect racial differences. Further research with larger sam-
ples of pregnancies complicated by Down syndrome is needed. 
  Meanwhile, factors affecting the performance of Down syn-
drome screening include the use of ultrasound scans to estimate 
gestational age, maternal weight, insulin-dependent diabetes, 
and smoking (21-25). Of these factors, insulin-dependent dia-
betes and smoking were not taken into account in this study, as 
the prevalence of insulin-dependent diabetics in Korea is ex-
tremely low, with a prevalence of 1.4 per 100,000, and very few 
Korean pregnant women smoke cigarettes. 
  In conclusion, we introduce a more accurate and efficient 
screening method for antenatal Down syndrome screening 
based on a Korean-specifc parameter set. With the proposed 
parameter model, quadruple screening can detect 81.8% of preg-
nancies complicated by Down syndrome in the second trimes-
ter with a false-positive rate of 6.6% at a cut-off value of 1:250 in 
Korea. Future research is needed to develop the specified guide-
line of genetic counseling based on the larger samples for Kore-
an women. 
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